The Johns Hopkins-led and NIH funded OUtMATCH study led to the development of Xolair, a groundbreaking drug that reduces the ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the respiratory community has seen a continuous growth in the number of biologics ...